CAT

895.55

-0.06%↓

296.7

-1.99%↓

GEV.US

1,039.92

-0.5%↓

RTX

175.97

-0.46%↓

237.55

+2.79%↑

CAT

895.55

-0.06%↓

296.7

-1.99%↓

GEV.US

1,039.92

-0.5%↓

RTX

175.97

-0.46%↓

237.55

+2.79%↑

CAT

895.55

-0.06%↓

296.7

-1.99%↓

GEV.US

1,039.92

-0.5%↓

RTX

175.97

-0.46%↓

237.55

+2.79%↑

CAT

895.55

-0.06%↓

296.7

-1.99%↓

GEV.US

1,039.92

-0.5%↓

RTX

175.97

-0.46%↓

237.55

+2.79%↑

CAT

895.55

-0.06%↓

296.7

-1.99%↓

GEV.US

1,039.92

-0.5%↓

RTX

175.97

-0.46%↓

237.55

+2.79%↑

Начало・Списък с акции・Ocugen Inc

Ocugen Inc

Затворен

1.51 4.86

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.44

Максимум

1.51

Ключови измерители
By Trading Economics
Приходи	2.3M -18M
Продажби	-1.9M -193K
Марж на печалбата	9,174.093
Служители	116
EBITDA	1.5M -16M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+703.47% upside

Дивиденти
By Dow Jones
Следващи печалби	31.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-8.7M 626M
Предишно отваряне	-3.35
Предишно затваряне	1.51

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

0.6818 / 0.74 Подкрепа & съпротива

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.05.2026 г., 23:55 ч. UTC

Печалби

Review & Preview: Still Going Strong -- Barrons.com

8.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 20:49 ч. UTC

Печалби

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8.05.2026 г., 20:25 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Net $115M

8.05.2026 г., 19:20 ч. UTC

Пазарно говорене

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8.05.2026 г., 19:18 ч. UTC

Печалби

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8.05.2026 г., 19:16 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:08 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:05 ч. UTC

Печалби

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8.05.2026 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8.05.2026 г., 18:51 ч. UTC

Печалби

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8.05.2026 г., 18:49 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 18:41 ч. UTC

Печалби

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8.05.2026 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8.05.2026 г., 17:14 ч. UTC

Печалби

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8.05.2026 г., 17:04 ч. UTC

Пазарно говорене

Zcash Caps Off Parabolic Week -- Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.05.2026 г., 15:39 ч. UTC

Пазарно говорене

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8.05.2026 г., 15:39 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.05.2026 г., 15:39 ч. UTC

Пазарно говорене

Canada's Job Market Sees Worst Start in Years -- Market Talk

8.05.2026 г., 15:36 ч. UTC

Пазарно говорене

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8.05.2026 г., 15:20 ч. UTC

Пазарно говорене

'Altcoin Season' Indicator on the Rise -- Market Talk

8.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Печалби

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8.05.2026 г., 15:05 ч. UTC

Пазарно говорене

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8.05.2026 г., 14:42 ч. UTC

Пазарно говорене

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8.05.2026 г., 14:39 ч. UTC

Пазарно говорене

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

703.47% нагоре

12-месечна прогноза

Среден 11.57 USD 703.47%

Висок 22 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.6818 / 0.74Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.